These studies were followed by the DESTINY-Lung02 trial exploring two different doses, which led to the FDA approval of the 5.4 mg/kg dose in lung cancers with HER2 mutations after prior platinum-based chemotherapy [2]. This evidence concerns the gene ERBB2 and lung carcinoma.